Summary

The 7 major metachromatic leukodystrophy markets reached a value of US$ 2.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.2 Billion by 2034, exhibiting a growth rate (CAGR) of 4.8% during 2024-2034.

The Metachromatic Leukodystrophy Market has been comprehensively analyzed in IMARC's new report titled "Metachromatic Leukodystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034". Metachromatic leukodystrophy refers to a rare hereditary (genetic) disorder characterized by the accumulation of fatty substances (lipids) in cells, particularly in the spinal cord, brain, and peripheral nerves. This buildup is caused by the deficiency of an enzyme that aids in the breakdown of lipids called sulfatides. Based on the age at which symptoms manifest, there are three distinct types of metachromatic leukodystrophy: adult metachromatic leukodystrophy, juvenile metachromatic leukodystrophy, and late-infantile metachromatic leukodystrophy. The mutations in the ARSA gene and, in rare circumstances, the PSAP gene lead to metachromatic leukodystrophy. Each metachromatic leukodystrophy subtype has specific symptoms and rate of progression. Each subtype is based on the age of onset. All forms of metachromatic leukodystrophy are progressive. Symptoms vary depending on the type but generally include behavioral and personality problems, difficulties speaking, seizures, trouble walking, and personality changes. In late-infantile metachromatic leukodystrophy, within months of the first symptoms, most children lose the ability to talk and walk. The diagnosis of metachromatic leukodystrophy is made through both genetic and biochemical testing. Genetic testing can identify mutations in the ARSA and PSAP genes. Biochemical testing includes sulfatase enzyme activity and urinary sulfatide excretion. An MRI shows imaging of a person's brain and can reveal the presence or absence of myelin. There is a classic pattern of myelin loss in the brains of individuals affected by metachromatic leukodystrophy.

The rising incidences of genetic abnormalities coupled with the increasing demand for effective medications that can treat such conditions are primarily driving the market for metachromatic leukodystrophy. In addition to this, the introduction of a wide variety of innovative pharmacological compounds for the symptomatic alleviation of metachromatic leukodystrophy is also creating a positive outlook for the market. These products are effective in preventing nerve damage, slowing the progression of the disorder, and reducing further complications. Moreover, the widespread adoption of gene therapy for treating early-onset metachromatic leukodystrophy in pediatric patients is also propelling the market growth. Besides this, several governing bodies and non-governmental organizations (NGOs) are supporting various health education campaigns to generate awareness among the masses regarding the symptoms, treatments, and benefits of early diagnosis of rare diseases, including metachromatic leukodystrophy. This, in turn, is further acting as a significant growth-inducing factor. Additionally, the ongoing development of novel therapies, such as hematopoietic stem cell transplantation, which utilizes both umbilical cord blood and bone marrow sources to treat the disease, is expected to drive the metachromatic leukodystrophy market in the coming years.

IMARC Group's new report "Metachromatic Leukodystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Metachromatic Leukodystrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Metachromatic Leukodystrophy market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Metachromatic Leukodystrophy across the seven major markets. According to the report the United States has the largest patient pool for Metachromatic Leukodystrophy and also represents the largest market for Metachromatic Leukodystrophy treatment. Furthermore, the current Metachromatic Leukodystrophy treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Metachromatic Leukodystrophy market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, Current and Future Epidemiology Scenario
Historical, Current and Future Performance of the Metachromatic Leukodystrophy Market
Historical, Current and Future Performance of Various Therapeutic Categories in the Metachromatic Leukodystrophy Market
Sales of Various Drugs Across the Metachromatic Leukodystrophy Market
Reimbursement Scenario in the Metachromatic Leukodystrophy Market
In-Market and Pipeline Drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Metachromatic Leukodystrophy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the Metachromatic Leukodystrophy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Metachromatic Leukodystrophy market across the seven major markets in 2023 and how will it look like in 2034?
What is the growth rate of the Metachromatic Leukodystrophy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Metachromatic Leukodystrophy market?

Epidemiology Insights

What is the size of the Metachromatic Leukodystrophy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Metachromatic Leukodystrophy across the seven major markets?
What are the key factors driving the epidemiological trend of Metachromatic Leukodystrophy?
What will be the growth rate of Metachromatic Leukodystrophy patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed Metachromatic Leukodystrophy drugs and what are their market performance?
What are the key pipeline Metachromatic Leukodystrophy drugs and how are they expected to perform in the coming years?
How safe are the current marketed Metachromatic Leukodystrophy drugs and what are their efficacies?
How safe are the late-stage pipeline Metachromatic Leukodystrophy drugs and what are their efficacies?
What are the current treatment guidelines for Metachromatic Leukodystrophy drugs across the seven major markets?
Who are the key companies in the Metachromatic Leukodystrophy market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Metachromatic Leukodystrophy market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Metachromatic Leukodystrophy - Introduction
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence

5 Metachromatic Leukodystrophy - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Metachromatic Leukodystrophy - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)

8 Metachromatic Leukodystrophy - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Metachromatic Leukodystrophy Guidelines, Management and Treatment
8.2 Metachromatic Leukodystrophy Treatment Algorithm

9 Metachromatic Leukodystrophy - Unmet Needs

10 Metachromatic Leukodystrophy - Key Endpoints of Treatment

11 Metachromatic Leukodystrophy - Marketed Products
11.1 List of Metachromatic Leukodystrophy Marketed Drugs Across the Top 7 Markets
11.1.1 Libmeldy (Atidarsagene autotemcel) - Orchard Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Metachromatic Leukodystrophy - Pipeline Drugs
12.1 List of Metachromatic Leukodystrophy Pipeline Drugs Across the Top 7 Markets
12.1.1 Cerebroside sulfatase - Takeda
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Metachromatic Leukodystrophy - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Metachromatic Leukodystrophy - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Metachromatic Leukodystrophy - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Metachromatic Leukodystrophy - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Metachromatic Leukodystrophy - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Metachromatic Leukodystrophy - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Metachromatic Leukodystrophy - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Metachromatic Leukodystrophy - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Metachromatic Leukodystrophy - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Metachromatic Leukodystrophy - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Metachromatic Leukodystrophy - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Metachromatic Leukodystrophy - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Metachromatic Leukodystrophy - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Metachromatic Leukodystrophy - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Metachromatic Leukodystrophy - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Metachromatic Leukodystrophy - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Metachromatic Leukodystrophy - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Metachromatic Leukodystrophy - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Metachromatic Leukodystrophy - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Metachromatic Leukodystrophy - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Metachromatic Leukodystrophy - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Metachromatic Leukodystrophy - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Metachromatic Leukodystrophy - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Metachromatic Leukodystrophy - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Metachromatic Leukodystrophy - Access and Reimbursement Overview

15 Metachromatic Leukodystrophy - Recent Events and Inputs From Key Opinion Leaders

16 Metachromatic Leukodystrophy Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats

17 Appendix